Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Alpelisib fills a gap in the treatment of HR/HER2- breast cancer, particularly in patients with PIK3CA mutations, and the combination of fulvestrant improves efficacy.Who is Alpeli···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：222
For patients with advanced HR/HER2- breast cancer, the combination of Alpelisib and fulvestrant is a precision treatment for PIK3CA mutations.Who is Alpelisib for?Alpelisib is suit···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：143
As a PIK3CA inhibitor, Alpelisib works synergistically with fulvestrant to significantly improve the prognosis of breast cancer patients with HR/HER2- and PIK3CA mutations.What is ···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：206
Alpelisib effectively inhibits the proliferation of HR/HER2- breast cancer cells by inhibiting the PI3K pathway, which is especially suitable for advanced cases with PIK3CA mutatio···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：191
The combination of Alpelisib and fulvestrant specifically targeted patients with advanced breast cancer with HR/HER2- and PIK3CA mutations significantly prolongs progression-free s···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：184
Koselugois a multifunctional targeted therapy drug, which can be used as a small molecule MEK inhibitor for the treatment of low-grade serous ovarian cancer, etc., and as a tyrosin···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：209
Koselugo is a targeted therapy that targets specific cancers by inhibiting the activity of key enzymes to block the growth of cancer cells.Which drugs interact with KoselugoThere a···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：239
Koselugo is a targeted therapy drug for the treatment of low-grade serous ovarian cancer, neurofibromas, etc., by inhibiting MEK protein kinase and RET tyrosine kinase activity.Wha···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：235
Koselugois an anti-cancer drug targeting MEK protein, which can successfully block cell signaling pathways and inhibit the proliferation of tumor cells, with significant and superi···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：208
Koselugo is an MEK protein-targeted anticancer agent that can effectively cut the cell signaling chain and inhibit the proliferation of tumor cells, showing excellent therapeutic e···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：212
Koselugo is an anti-cancer drug targeting MEK protein, which inhibits tumor cell proliferation by blocking cell signaling and has significant efficacy in specific cancer types.What···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：277
By targeting and inhibiting the activity of MEK protein, Koselugo effectively cuts off the signaling pathway of tumor cells, thereby inhibiting their abnormal proliferation, bringi···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：250
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3172024-09-07
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：132025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：232025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：272025-27-11
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended：3062025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended：2712025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended：3502024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended：2492024-24-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
